Opportunities for translation: Targeting DNA repair pathways in pancreatic cancer

被引:14
作者
Maginn, Elaina N. [1 ]
de Sousa, Camila H. [1 ]
Wasan, Harpreet S. [1 ]
Stronach, Euan A. [1 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Canc & Surg, Mol Therapy Lab, Du Cane Rd, London W12 0NN, England
来源
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER | 2014年 / 1846卷 / 01期
关键词
Pancreatic ductal adenocarcinoma; DNA damage response and repair; DNA damaging agents; Chemoresistance; PHASE-II TRIAL; NUCLEOTIDE EXCISION-REPAIR; BRCA2 GERMLINE MUTATIONS; COMPLEMENTATION GROUP 1; CROSS-LINK REPAIR; LUNG-CANCER; POLY(ADP-RIBOSE) POLYMERASE; HOMOLOGOUS RECOMBINATION; DAMAGE RESPONSE; ERCC1; EXPRESSION;
D O I
10.1016/j.bbcan.2014.04.002
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Pancreatic ductal adenocarcinoma (PDAC) remains one of the poorest prognosis neoplasms. It is typified by high levels of genomic aberrations and copy-number variation, intra-tumoural heterogeneity and resistance to conventional chemotherapy. Improved therapeutic options, ideally targeted against cancer-specific biological mechanisms, are urgently needed. Although induction of DNA damage and/or modulation of DNA damage response pathways are associated with the activity of a number of conventional PDAC chemotherapies, the effectiveness of this approach in the treatment of PDAC has not been comprehensively reviewed. Here, we review chemotherapeutic agents that have shown anti-cancer activity in PDAC and whose mechanisms of action involve modulation of DNA repair pathways. In addition, we highlight novel potential targets within these pathways based on the emerging understanding of PDAC biology and their exploitation as targets in other cancers. (C) 2014 Elsevier B.V. All rights reserved.
引用
收藏
页码:45 / 54
页数:10
相关论文
共 170 条
[1]   Ovarian cancer: Strategies for overcoming resistance to chemotherapy [J].
Agarwal, R ;
Kaye, SB .
NATURE REVIEWS CANCER, 2003, 3 (07) :502-516
[2]   Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma [J].
Akita, H. ;
Zheng, Z. ;
Takeda, Y. ;
Kim, C. ;
Kittaka, N. ;
Kobayashi, S. ;
Marubashi, S. ;
Takemasa, I. ;
Nagano, H. ;
Dono, K. ;
Nakamori, S. ;
Monden, M. ;
Mori, M. ;
Doki, Y. ;
Bepler, G. .
ONCOGENE, 2009, 28 (32) :2903-2909
[3]   Harnessing the complexity of DNA-damage response pathways to improve cancer treatment outcomes [J].
Al-Ejeh, F. ;
Kumar, R. ;
Wiegmans, A. ;
Lakhani, S. R. ;
Brown, M. P. ;
Khanna, K. K. .
ONCOGENE, 2010, 29 (46) :6085-6098
[4]   Germline BRCA1 mutations predispose to pancreatic adenocarcinoma [J].
Al-Sukhni, Wigdan ;
Rothenmund, Heidi ;
Borgida, Ayelet Eppel ;
Zogopoulos, George ;
O'Shea, Anne-Marie ;
Pollett, Aaron ;
Gallinger, Steven .
HUMAN GENETICS, 2008, 124 (03) :271-278
[5]   A Medicinal Chemistry Perspective for Targeting Histone H3 Lysine-79 Methyltransferase DOT1 L [J].
Anglin, Justin L. ;
Song, Yongcheng .
JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (22) :8972-8983
[6]  
[Anonymous], COCHRANE DATAB SYST
[7]   Prognostic factors in gemcitabine-cisplatin polychemotherapy regimens in pancreatic cancer: XPD-Lys751Gln polymorphism strikes back [J].
Avan, Amir ;
Pacetti, Paola ;
Reni, Michele ;
Milella, Michele ;
Vasile, Enrico ;
Mambrini, Andrea ;
Vaccaro, Vanja ;
Caponi, Sara ;
Cereda, Stefano ;
Peters, Godefridus J. ;
Cantore, Maurizio ;
Giovannetti, Elisa .
INTERNATIONAL JOURNAL OF CANCER, 2013, 133 (04) :1016-1022
[8]  
Azmi AS, 2011, ONCOTARGET, V2, P378
[9]   MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function [J].
Azmi, Asfar S. ;
Aboukameel, Amro ;
Banerjee, Sanjeev ;
Wang, Zhiwei ;
Mohammad, Momin ;
Wu, Jack ;
Wang, Shaomeng ;
Yang, Dajun ;
Philip, Philip A. ;
Sarkar, Fazlul H. ;
Mohammad, Ramzi M. .
EUROPEAN JOURNAL OF CANCER, 2010, 46 (06) :1122-1131
[10]   Targeting DOT1L action and interactions in leukemia: the role of DOT1L in transformation and development [J].
Barry, Evan R. ;
Corry, Gareth N. ;
Rasmussen, Theodore P. .
EXPERT OPINION ON THERAPEUTIC TARGETS, 2010, 14 (04) :405-418